In vivo results demonstrated a significantly higher cellular uptake efficiency and number of dead PCa cells with the targeted nanoprobe compared to non-targeted interventions, supporting the importance of CD133-targeting in therapeutic efficacy [125]. Here, PROM1 is linked to posterior cortical atrophy.